RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

RFA Plus Carrizumab vs Carrizumab Alone for HCC

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04150744, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Diagnosis as hepatocellular carcinoma from histology and cytology

    Inclusion criterion 2

  3. Score of ECOG PS: 0-2

    Inclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04150744, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age from 18-75 years
  • Diagnosis as hepatocellular carcinoma from histology and cytology
  • BCLC B-C degree
  • Score of ECOG PS: 0-2
  • Child-Pugh Score: A or B
  • Not suitable for resection or liver transplantation
  • Have not received systemic therapy
  • Have at least one evaluable target mass from CT or MRI according to mRECIST
  • The estimated survival time ≥ 12 weeks
  • Patients with HBV infection having HBV-DNA <500IU/mL and standard anti-virus treatment. Patients with HCV infection must receive standard anti-virus treatment.
  • The function of main organs normal
  • Sign informed consent

Exclusion Criteria:

  • Have cholangiocarcinoma, mixed type of hepatocarcinoma and fibrolamellar hepatocellular carcinoma. Have incurable malignant tumor in five years.
  • Have local ablation, TACE or radiotherapy in 3 months before enrolled.
  • Prepared to or have received organic or bone marrow transplantation.
  • Uncontrollable ascites, hepatic encephalopathy or esophageal and gastric varices.
  • Have hypertension and can't lower down to the normal level using blood pressure medication.
  • Have type II myocardial ischemia or myocardial infarction, uncontrollable arrhythmia.
  • Have diseases to influent the effect of oral drugs, for example, unable to swallow, chronic diarrhea and intestinal obstruction.
  • Have gastrointestinal bleeding in 6 months
  • Have abdominal fistula, gastrointestinal perforation or abdominal abscess
  • Patients with lung fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug related pneumonia or severe dysfunction of lung.
  • Routine urine test showed urinary protein ≥++ or the 24 hours amount of urinary protein ≥1.0 g
  • Patients have autoimmune disease
  • Patients need corticosteroid or other immunosuppressant therapy
  • Patients have anti-tumor vaccine and other immunostimulate anti-tumor drugs in 3 months
  • Allergy to monocloning antibody
  • Pregnant or breastfeeding female Other patients not suitable to be enrolled in the study.

Quoted from ClinicalTrials.gov, NCT04150744, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04150744, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04150744